Immatics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Immatics and other ETFs, options, and stocks.About IMTX
Immatics NV is a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer. Its pipeline includes adoptive cell therapy and TCR Bispecifics.
CEOHarpreet Singh-Jasuja
CEOHarpreet Singh-Jasuja
Employees423
Employees423
HeadquartersTuebingen, Baden Wuerttemberg
HeadquartersTuebingen, Baden Wuerttemberg
Founded2020
Founded2020
Employees423
Employees423
IMTX Key Statistics
Market cap1.33B
Market cap1.33B
Price-Earnings ratio-9.23
Price-Earnings ratio-9.23
Dividend yield—
Dividend yield—
Average volume638.92K
Average volume638.92K
High today$10.24
High today$10.24
Low today$9.87
Low today$9.87
Open price$10.10
Open price$10.10
Volume691.38K
Volume691.38K
52 Week high$12.41
52 Week high$12.41
52 Week low$3.30
52 Week low$3.30
Stock Snapshot
With a market cap of 1.33B, Immatics(IMTX) trades at $9.92. The stock has a price-to-earnings ratio of -9.23.
As of 2025-12-17, Immatics(IMTX) stock has fluctuated between $9.87 and $10.24. The current price stands at $9.92, placing the stock +0.5% above today's low and -3.1% off the high.
Immatics(IMTX) shares are trading with a volume of 691.38K, against a daily average of 638.92K.
In the last year, Immatics(IMTX) shares hit a 52-week high of $12.41 and a 52-week low of $3.30.
In the last year, Immatics(IMTX) shares hit a 52-week high of $12.41 and a 52-week low of $3.30.
Analyst ratings
100%
of 11 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own IMTX. This list is generated using Robinhood data, and it’s not a recommendation.